Atrial Fibrillation (AF) is the most common treated heart arrhythmia and affects 2.5% of the western world.
Complications include end-organ damage (stroke), AF progression, heart failure, collapse and iatrogenic bleeding.
Long episodes of AF are associated with increased stroke risk and hospitalization; episodes > 24 hours triple the risk of stroke and increase hospitalization.
Ablation is the gold standard treatment for AF, however, it is resource-intensive and availability is limited. Ablation is applicable to a small minority of AF patients. There is an unmet need for a safe and effective antiarrhythmic drug to reduce the frequency and duration of long harmful episodes to improve outcomes.
In two Phase II clinical trials, our NCE antiarrhytmic drug has been shown to suppress AF burden, eliminate long episodes and improve symptoms in a dose-dependent fashion whilst maintaining a favourable safety profile.
With dose titration, our NCE could eliminate episodes >24 hours by up to 100% compared to placebo.
Wearable devices enable a passive, cost-effective and intuitive method of monitoring AF with a wide installed base for AF duration and burden monitoring without the need for clinic visits.
We intend to enter late-stage clinical trials using a combination of our NCE with a wearable device to create a complete package for early detection and treatment to improve long-term outcomes in AF.
Complications include end-organ damage (stroke), AF progression, heart failure, collapse and iatrogenic bleeding.
Long episodes of AF are associated with increased stroke risk and hospitalization; episodes > 24 hours triple the risk of stroke and increase hospitalization.
Ablation is the gold standard treatment for AF, however, it is resource-intensive and availability is limited. Ablation is applicable to a small minority of AF patients. There is an unmet need for a safe and effective antiarrhythmic drug to reduce the frequency and duration of long harmful episodes to improve outcomes.
In two Phase II clinical trials, our NCE antiarrhytmic drug has been shown to suppress AF burden, eliminate long episodes and improve symptoms in a dose-dependent fashion whilst maintaining a favourable safety profile.
With dose titration, our NCE could eliminate episodes >24 hours by up to 100% compared to placebo.
Wearable devices enable a passive, cost-effective and intuitive method of monitoring AF with a wide installed base for AF duration and burden monitoring without the need for clinic visits.
We intend to enter late-stage clinical trials using a combination of our NCE with a wearable device to create a complete package for early detection and treatment to improve long-term outcomes in AF.